Serum Metabolomics Benefits Discrimination Kidney Disease Development in Type 2 Diabetes Patients

Serum Metabolomics Benefits Discrimination Kidney Disease Development in Type 2 Diabetes Patients

BackgroundDiabetic kidney disease (DKD) is the primary cause of end-stage renal disease, raising a considerable burden worldwide. Recognizing novel biomarkers by metabolomics can shed light on new biochemical insight to benefit DKD diagnostics and therapeutics. We hypothesized that serum metabolites...

Full description

Bibliographic Details
Main Authors: Xiaofeng Peng, Xiaoyi Wang, Xue Shao, Yucheng Wang, Shi Feng, Cuili Wang, Cunqi Ye, Jianghua Chen, Hong Jiang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Medicine
Subjects:
diabetic kidney disease
metabolomics
proteinuria
biomarker discovery
progression
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.819311/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.819311/full

Similar Items